Sherlock Biosciences

Sherlock Biosciences: Series C Funding Round

Sherlock Biosciences has successfully raised $220M in Series C funding, reaching a valuation of $1.5B.

Company Overview

CRISPR-powered diagnostics

Funding Details

The Series C round was led by Vivo Capital, with participation from Baillie Gifford, GV, Taiho Ventures, Perceptive Advisors, William K. Warren Foundation.

Company Information

• Headquarters: 201 Brookline Avenue, Boston, MA 02215
• Founded: 2019
• Employees: 150+
• Category: Biotech

Investment

Sherlock Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

• Vivo Capital: Verified investor in Series C
• Baillie Gifford: Verified investor in Series C
• GV: Verified investor in Series C
• Taiho Ventures: Verified investor in Series C
• Perceptive Advisors: Verified investor in Series C
• William K. Warren Foundation: Verified investor in Series C